Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study

• Published in: Journal of neurology Vol. 269; no. 7; pp. 3676 - 3681
• Main Authors: Alcalá, Carmen, Quintanilla-Bordás, Carlos, Gascón, Francisco, Sempere, Ángel Perez, Navarro, Laura, Carcelén-Gadea, María, Landete, Lamberto, Mallada, Javier, Cañizares, Emmanuel, Belenguer, Antonio, Carratalá, Sara, Domínguez, José Andrés, Pérez-Miralles, Francisco Carlos, Gil-Perotín, Sara, Gasqué, Raquel, Cubas, Laura, Castillo, Jéssica, Casanova, Bonaventura
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.07.2022; Springer Nature B.V
• Subjects: Immunotherapy; Medicine; Medicine & Public Health; Monoclonal antibodies; Multiple sclerosis; Neurology; Neuroradiology; Neurosciences; Observational studies; Original Communication; Patients; Rituximab; Survival analysis; PPMS treatment ocrelizumab rituximab real-world effectiveness

Introduction Ocrelizumab, an antiCD-20 antibody, is the only drug approved to treat patients with primary progressive multiple sclerosis (pwPPMS). Not all candidates receive this treatment due to prescription limitations. Rituximab, another antiCD-20 antibody, has been used off-label in pwPPMS befor...